Macular Edema Following Branch Retinal Vein Occlusion

• FDA approval · 2023-12-14
  FDA Approved: EYLEA — Supplemental Application (Regeneron Pharmaceuticals, Inc.)

  The FDA approved a supplemental application for EYLEA (aflibercept) from Regeneron Pharmaceuticals, Inc.

• FDA label_change · 2023-12-14
  FDA Approved: EYLEA HD — Supplemental Application (Regeneron Pharmaceuticals, Inc)

  FDA approved a supplemental application for EYLEA HD (aflibercept) from Regeneron, indicating a labeling change for the high-dose formulatio…

• FDA approval · 2021-09-17
  FDA Approved: BYOOVIZ — Original Application (BIOGEN INC.)

  BYOOVIZ, Biogen's ranibizumab-nuna biosimilar, has been approved by the FDA through its Original Application, with indications matching thos…

• FDA approval · 2009-06-17
  FDA Approved: OZURDEX — Original Application (Allergan, Inc.)

  FDA granted the original approval for Ozurdex (dexamethasone intravitreal implant) by Allergan for the treatment of macular edema following …

• FDA approval ·
  FDA Approved: OZURDEX — Supplemental Application (Allergan, Inc.)

  The FDA approved a supplemental application for OZURDEX (dexamethasone) by Allergan, Inc.

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.